<DOC>
	<DOCNO>NCT01860326</DOCNO>
	<brief_summary>This open-label study evaluate pharmacokinetics , safety tolerability single oral dos Alisporivir subject mild moderate hepatic impairment compare match healthy subject normal liver function .</brief_summary>
	<brief_title>Evaluate Pharmacokinetics , Safety , Tolerability Alisporivir Subjects With Hepatic Impairment Compared Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<criteria>Inclusion criterion : Male female , 18 70 year age , good health Stable ChildTurcottePugh score least 5 Body weight least 50 kg BMI 18.0 36.0 kg/m2 Exclusion criterion : Use investigational drug Women childbearing potential Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>hepatic impairment</keyword>
	<keyword>mild moderate hepatic impairment</keyword>
	<keyword>Alisporivir</keyword>
</DOC>